NEUMORA THERAPEUTICS, INC. Net Income
NEUMORA THERAPEUTICS, INC. (NMRA) reported Net Income of -$43.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-14
- NEUMORA THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$43.08M.
- NEUMORA THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$53.46M.
- NEUMORA THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $414.41M, a 3.35% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$56.76M.
- NEUMORA THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2023 was -$235.93M.
- NEUMORA THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2022 was -$130.90M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$43.08M 10-Q · filed 2026-08-14 | -$96.54M 10-Q · filed 2026-08-14 | $317.87M derived: sum of 3 quarters · filed 2026-08-14 | $261.11M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | -$53.46M 10-Q · filed 2026-08-14 | $360.95M derived: sum of 2 quarters · filed 2026-08-14 | $304.19M derived: sum of 3 quarters · filed 2026-08-14 | $251.46M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $414.41M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-17 | $357.65M derived: sum of 2 quarters · filed 2026-04-17 | $304.92M derived: sum of 3 quarters · filed 2026-08-14 | $236.93M DEF 14A · filed 2026-04-17 | -$236.93M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$56.76M 10-Q · filed 2025-11-06 | -$109.49M derived: sum of 2 quarters · filed 2026-08-14 | -$177.48M 10-Q · filed 2025-11-06 | $251.28M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | -$52.73M 10-Q · filed 2026-08-14 | -$120.72M 10-Q · filed 2026-08-14 | $308.03M derived: sum of 3 quarters · filed 2026-08-14 | $235.49M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | -$67.99M 10-Q · filed 2026-08-14 | $360.76M derived: sum of 2 quarters · filed 2026-08-14 | $288.22M derived: sum of 3 quarters · filed 2026-08-14 | $229.52M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2024-12-31 | $428.75M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-17 | $356.21M derived: sum of 2 quarters · filed 2026-04-17 | $297.51M derived: sum of 3 quarters · filed 2026-04-17 | $243.79M DEF 14A · filed 2026-04-17 | -$243.79M 10-K · filed 2025-03-03 |
| 2024-09-30 | -$72.55M 10-Q · filed 2025-11-06 | -$131.25M derived: sum of 2 quarters · filed 2025-11-06 | -$184.97M 10-Q · filed 2025-11-06 | -$293.70M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | -$58.70M 10-Q · filed 2025-11-06 | -$112.42M 10-Q · filed 2025-08-06 | -$221.15M derived: sum of 3 quarters · filed 2025-11-06 | -$274.18M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-03-31 | -$53.72M 10-Q · filed 2025-11-06 | -$162.45M derived: sum of 2 quarters · filed 2025-11-06 | -$215.48M derived: sum of 3 quarters · filed 2025-11-06 | -$254.02M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2023-12-31 | -$108.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$161.76M derived: sum of 2 quarters · filed 2025-03-03 | -$200.30M derived: sum of 3 quarters · filed 2025-03-03 | -$235.93M 10-K · filed 2025-03-03 | |
| 2023-09-30 | -$53.03M 10-Q · filed 2024-11-12 | -$91.57M derived: sum of 2 quarters · filed 2024-11-12 | -$127.19M 10-Q · filed 2024-11-12 | -$155.34M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | -$38.54M 10-Q · filed 2024-11-12 | -$74.17M 10-Q · filed 2024-08-06 | -$102.31M derived: sum of 3 quarters · filed 2025-03-03 | -$131.66M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | -$35.63M 10-Q · filed 2024-11-12 | -$63.77M derived: sum of 2 quarters · filed 2025-03-03 | -$93.11M derived: sum of 3 quarters · filed 2025-03-03 | -$123.49M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2022-12-31 | -$28.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$57.49M derived: sum of 2 quarters · filed 2025-03-03 | -$87.86M derived: sum of 3 quarters · filed 2025-03-03 | -$130.90M 10-K · filed 2025-03-03 | |
| 2022-09-30 | -$29.34M 10-Q · filed 2023-11-01 | -$59.72M derived: sum of 2 quarters · filed 2023-11-01 | -$102.76M 10-Q · filed 2023-11-01 | ||
| 2022-06-30 | -$30.37M 10-Q · filed 2023-11-01 | -$73.41M derived: sum of 2 quarters · filed 2023-11-01 | |||
| 2022-03-31 | -$43.04M 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |